{"id":842572,"date":"2022-12-14T06:06:34","date_gmt":"2022-12-14T05:06:34","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/"},"modified":"2022-12-14T06:06:34","modified_gmt":"2022-12-14T05:06:34","slug":"catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/","title":{"rendered":"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors"},"content":{"rendered":"MUNICH--(BUSINESS WIRE)--CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue.\n\n\n\n\u201cThe success of our Series
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

MUNICH–(BUSINESS WIRE)–CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the continued, […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49624],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-842572","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-europe"],"acf":[],"yoast_head":"\nCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - BeBeez\" \/>\n<meta property=\"og:description\" content=\"MUNICH--(BUSINESS WIRE)--CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the continued, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-14T05:06:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors\",\"datePublished\":\"2022-12-14T05:06:34+00:00\",\"dateModified\":\"2022-12-14T05:06:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/\"},\"wordCount\":939,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in Europe\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/\",\"name\":\"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-12-14T05:06:34+00:00\",\"dateModified\":\"2022-12-14T05:06:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - BeBeez","og_description":"MUNICH--(BUSINESS WIRE)--CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the continued, […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/","og_site_name":"BeBeez","article_published_time":"2022-12-14T05:06:34+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/"},"author":{"name":"","@id":""},"headline":"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors","datePublished":"2022-12-14T05:06:34+00:00","dateModified":"2022-12-14T05:06:34+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/"},"wordCount":939,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in Europe"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/","name":"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-12-14T05:06:34+00:00","dateModified":"2022-12-14T05:06:34+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/catalym-closes-eur-50-million-series-c-financing-to-expand-and-accelerate-phase-2-clinical-development-of-visugromab-in-patients-with-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/842572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=842572"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/842572\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=842572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=842572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=842572"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=842572"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=842572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}